Baseline clinical characteristics of NSCLC patients receiving nivolumab as second-or-more-line therapy.

Figshare2019-07-17 更新2026-04-29 收录

数据链接：

https://figshare.com/articles/dataset/Baseline_clinical_characteristics_of_NSCLC_patients_receiving_nivolumab_as_second-or-more-line_therapy_/8945837 数据链接链接失效反馈

官方服务：

资源简介：

Baseline clinical characteristics of NSCLC patients receiving nivolumab as second-or-more-line therapy.

创建时间：

2019-07-17

Table_2_Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer.docx

非小细胞肺癌免疫治疗

生存期替代终点

BackgroundThe combination of immune checkpoint inhibitors (ICIs) and chemotherapy is known to improve overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC). ICIs have

NIAID Data Ecosystem40

Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer. Omics study of SCLC

整合肿瘤学

非小细胞肺癌免疫治疗

Small cell lung cancer (SCLC) is highly invasive and lethal. Genomic studies are beginning to characterize its genetic determinants and heterogeneity. We performed RNA-Seq and whoe exome sequencing (W

NIAID Data Ecosystem30

Dataset from A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).

非小细胞肺癌免疫治疗

III期临床试验

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-b

NIAID Data Ecosystem10

Data and metadata supporting the published article: Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes

非小细胞肺癌免疫治疗

病理反应评估

Neoadjuvant immunotherapy provides a unique opportunity for understanding therapeutic responses. In this study, the authors analyzed pathologic responses in surgical specimens obtained from 31 squamou

NIAID Data Ecosystem40

DataSheet_1_Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.docx

免疫检查点抑制剂肺炎

非小细胞肺癌免疫治疗

Immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death- ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has revolutionized the therapeutic strategy

NIAID Data Ecosystem20

Baseline clinical characteristics of NSCLC patients receiving nivolumab as second-or-more-line therapy.

资源简介：

相关数据集